2008
DOI: 10.2147/tcrm.s1433
|View full text |Cite
|
Sign up to set email alerts
|

Update on local anesthetics: focus on levobupivacaine

Abstract: In recent years levobupivacaine, the pure S (−)-enantiomer of bupivacaine, emerged as a safer alternative for regional anesthesia than its racemic parent. It demonstrated less affinity and strength of depressant effects onto myocardial and central nervous vital centers in pharmacodynamic studies, and a superior pharmacokinetic profile. Clinically, levobupivacaine is well tolerated in a variety of regional anesthesia techniques both after bolus administration and continuous postoperative infusion. Reports of to… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
122
1
6

Year Published

2011
2011
2021
2021

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 128 publications
(132 citation statements)
references
References 88 publications
(106 reference statements)
3
122
1
6
Order By: Relevance
“…The major mechanism for bupivacaine depression of cardiac conduction is considered to be the fast block of Na + channels during action potential transmission, which results in slow recovery from block during diastole [23] . Recently, levobupivacaine, a single enantiomer of bupivacaine, has been introduced as a new long-acting LA with potentially reduced toxicity compared with bupivacaine [24] . Even so, bupivacaine has not been replaced in the market, probably due to the lack of perceived safety benefits and/or the consideration of additional costs for the switch to levobupivacaine, which is ~57% more expensive than bupivacaine [22] .…”
Section: Discussionmentioning
confidence: 99%
“…The major mechanism for bupivacaine depression of cardiac conduction is considered to be the fast block of Na + channels during action potential transmission, which results in slow recovery from block during diastole [23] . Recently, levobupivacaine, a single enantiomer of bupivacaine, has been introduced as a new long-acting LA with potentially reduced toxicity compared with bupivacaine [24] . Even so, bupivacaine has not been replaced in the market, probably due to the lack of perceived safety benefits and/or the consideration of additional costs for the switch to levobupivacaine, which is ~57% more expensive than bupivacaine [22] .…”
Section: Discussionmentioning
confidence: 99%
“…We used low-volume high-concentration longacting LA for maximal duration of analgesic effect via a single-injection ISB. 17,18 The blinded researcher then selected a sealed envelope and gave the envelope to the unblinded study team member. The unblinded member of the study team prepared the medication in a room adjacent to the operating theatre.…”
Section: Randomization Techniquementioning
confidence: 99%
“…Levobupivacaine and ropivacaine, new long-acting local anesthetics are S(-) enantiomers of two structurally similar molecules, 1-butyl-2' ,6'-pipecoloxylidide and 1-propyl-2' ,6'-pipecoloxylidide, respectively (18,19) and are been developed as safer alternatives to bupivacaine. Though less lipid-soluble than bupivacaine, ropivacaine is a long-acting spinal anesthetic.…”
Section: Introductionmentioning
confidence: 99%